Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma

Abroad (travel likely)Recruiting

Conditions

Extrahepatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Aichi Medical University, Aichi, Japan

  • Nagoya City University Hospital, Aichi, Japan

  • Nagoya City University Midori Municipal Hospital, Aichi, Japan

  • Gifu University Hospital, Gifu, Japan

  • Pusan National University Hospital, Busan, South Korea

  • Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

  • Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea

  • Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

Study leads
  • Tadahisa Inoue, Associate Professor

    Principal Investigator

    Department of Gastroenterology, Aichi Medical University

  • Jae Hee Cho, Professor

    Principal Investigator

    Department of Internal Medicine, Institute of Gastroenterology, Gangnam Severance Hospital, Yonsei University College of Medicine